Array licenses cancer compounds to Ono | Chemical & Engineering News
Volume 95 Issue 23 | p. 13 | Concentrates
Issue Date: June 5, 2017

Array licenses cancer compounds to Ono

Department: Business
Keywords: oncology, binimetinib, encorafenib, Array BioPharma

Array BioPharma has licensed Japan’s Ono Pharmaceutical the right to develop two late-stage oncology compounds, binimetinib and encorafenib, in Japan and South Korea. Array will get $32 million up front and up to $156 million in milestone payments. The compounds are in Phase III studies of patients with BRAF-mutant cancers. Array recently struck a deal to assess binimetinib with two Bristol-Myers Squibb immuno-oncology agents.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment